In the chart below, highlighted in blue, are the analyst’s 2016 estimated percentage changes for what the respective stock was expected to do. In red, we see what the actual outcome was for the stock in the past year.
Overall, we believe that the analysts covering the stocks on our watch list from last year did relatively well. The three stocks expected to underperform were on target. Only two of the ten stocks expected to increase failed to register on the positive side of the column.
“’Run your public company as if it were privately held, and you will be making the right decision for your public stockholders.’ And maybe you won’t be vulnerable to its being taken private at twice the current stock price… (page 23).”
On August 10, 2017, we executed the following transaction(s):
Previous Year Performance Review
In our ongoing review of the NLO Dividend Watch List, we have taken the top five stocks on our list from August 5, 2016 and have checked the performance one year later. The top five companies on that list can be seen in the table below.
||Gannett Co Inc
||National Penn Bancshares
||Capital City Bank Group
||Brown-Forman Corp. CL 'B'
||Wells Fargo &
||Dow Jones Industrial
Little was said about the top five companies in prior year. The one actionable item from our commentary was additional purchase of Carbo Ceramic (CRR) which didn't pan out well as oil supply continue to exceed demand. Despite that, the top five companies on our list returned 7% on average. The largest gain came from small regional bank Capital City Bank (CCBG). The biggest decline occurred in Gannett (GCI).
U.S. Dividend Watch List: August 4, 2017
The Dow reached another milestone breaking above 22,000 mark and closed the week at an all-time high. As a student of Dow Theory, it would be interesting to see Dow Jones Transport achieve the same mark. Despite that, we are still a continuation of a bull market. Below are companies on our watch list which we use as a starting point for our investment research. Continue reading
On August 3, 2017, Teva Pharmaceutial (TEVA) got slammed after the company reported a loss for the quarter and reduced its 2017 earnings expectations. Below is the updated Coppock Curve for TEVA .